Pyxis Oncology appoints Alex Kane as SVP of investor relations

BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) has appointed Alex Kane as Senior Vice President of Investor Relations & Capital Markets, effective immediately, the clinical-stage cancer therapeutics company announced Thursday.

Kane brings 20 years of experience in investor relations, strategic communications, and equity capital markets across the life sciences sector. He joins Pyxis from Guggenheim Securities, where he served as Vice President of Equity Capital Markets advising biotechnology clients on financing strategies.

Previously, Kane held senior investor relations positions at Praxis Precision Medicines and PTC Therapeutics, managing IPOs and secondary offerings. His earlier career included leadership roles at W2O Group, NASDAQ, and Thomson Reuters.

"Alex brings deep expertise in both investor relations and capital markets, and he is highly regarded for his ability to effectively communicate value-creation opportunities to the investment community," said Lara S. Sullivan, President, Chief Executive Officer and Chief Medical Officer of Pyxis Oncology.

Kane earned his MBA in Finance and Entrepreneurship from the NYU Stern School of Business and his BA in International Political Economy from Colorado College.

Pyxis Oncology is developing antibody-drug conjugate therapeutics for difficult-to-treat cancers. The company’s lead candidate, micvotabart pelidotin (MICVO), is currently being evaluated in clinical studies for multiple solid tumor types, with a focus on recurrent and metastatic head and neck squamous cell carcinoma.

According to the press release statement, the company has also initiated a Phase 1/2 combination study of MICVO with Merck’s anti-PD-1 therapy, KEYTRUDA.

In other recent news, Pyxis Oncology has been in the spotlight with several significant developments. Guggenheim has initiated coverage of Pyxis Oncology with a Buy rating, setting a price target of $5.00. This decision is based on the promising initial activity signals and predictable safety profile of MICVO, the company’s first-in-concept non-internalizing ADC, in its first-in-human phase 1 data. Additionally, Pyxis Oncology announced updates to patient enrollment for its Phase 1 clinical trial of micvotabart pelidotin, also known as MICVO. The trial, which is a first-in-human, open-label, multicenter study, aims to evaluate the safety and preliminary efficacy of MICVO in participants with advanced solid tumors. Revisions to the patient enrollment were posted on ClinicalTrials.gov, reflecting the maximum number of patients permitted according to the study protocol. Pyxis confirmed that the estimated number of head and neck squamous cell carcinoma patients in the dose expansion phase remains unchanged. These developments highlight Pyxis Oncology’s ongoing efforts in advancing its clinical trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.